Important Upcoming Events at SNMMI Annual Meeting in Baltimore

The Coalition would like to make you aware of some important events at the upcoming SNMMI annual meeting in Baltimore. We hope you can attend!

On Friday, June 5 from 9 to 10 am in the room Ruth in the Baltimore Hilton Hotel, the Coalition, led by Sally Schwarz, R.Ph. and Henry VanBrocklin, Ph.D., will hold a public meeting to review activities over the last year and to discuss future directions.

The Coalition is co-sponsoring a CE session with the Radiopharmaceutical Sciences Council (RPSC) on Monday, June 8, in Room 317 of the Baltimore Convention Center. The title of this session is “Current Topics in FDA Reviews and Inspections of PET Drug Manufacturers.” The session runs from 4:45 to 6:15 pm and includes the following presentations:

  • Current topics in FDA reviews and inspections from the perspective of a small entity, Steve Mattmuller, MS, RPh, BCNP
  • Current topics in FDA reviews and inspections from the commercial perspective, David Wilson, BS, RPh
  • Reporting changes to an approved NDA or ANDA, Michael Nazerias, M.S.
  • Overview of a sterility assurance program for PET drugs, Eric Webster

An additional session has recently been added to the program. The additional session is entitled “Update on Current Topics at the USP” and takes place immediately after the previous session on Monday, June 8, in Room 317 of the Baltimore Convention Center. The goal of the new session is to provide an update on the latest activities at the USP related to PET drug monographs and the revision of general chapters for PET drugs and radioactivity. In addition, information will be provided for the next revision cycle and future directions at the USP. The session runs from 6:20 pm to 6:50 pm and includes the following presentations:

  • Brief update on USP monographs for PET drugs, Steve Zigler, Ph.D.
  • Progress on general chapters pertinent to nuclear medicine, Steve Zigler, Ph.D.
  • Update on new revision cycle 2015-2020, Ravi Ravichandran, Ph.D.

Finally, a session entitled “FDA: Imaging Drug Development – Regulatory Issues” takes place on Tuesday, June 9, from 10:00 am to 11:30 am in Room 318-319 of the Baltimore Convention Center. This session is sponsored by the Health Policy and Regulatory Affairs group at SNMMI and includes the following presentations:

  • Chemistry, manufacturing, and control (CMC) issues in applications, Ravi Kasliwal, Ph.D.
  • Nonclinical requirements for low dose diagnostic agents: past, present, and envisioning the future, Adebayo Laniyonu, Ph.D.
  • Efficacy considerations for imaging product approval, Louis Marzella, MD, Ph.D.
  • Statistical aspects of evaluating diagnostics, Thomas Gwise, Ph.D.
  • PET products: case histories and inspectional updates, Krishna Gosh, Ph.D.
  • Ge-68/Ga-68 Generators – FDA perspective, John Amartey, Ph.D.
Advertisements
This entry was posted in PET Drugs. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s